Corporate Finance

Finance Roundup for Executives

Be informed, get involved, and shape the world through finance.
Kerry MarunaDecember 24, 2015

What’s Going on in Finance from CFO

Valeant Pharmaceuticals International will take a $150 million hit to its revenues from its new 20-year distribution deal with Walgreens Boots Alliance, according to the Wall Street Journal.

Thinkstock PharmaceuticalsAnalysts have generally applauded Valeant for finding a partner as respected as Walgreens to replace controversial mail-order pharmacy Philidor Rx Services. The Canadian company said last week it would team up with Walgreens to fill prescriptions for its skin, eye, and certain other drugs and help patients with out-of-pocket costs. Read more.

A Better Way to Do Ecommerce

A Better Way to Do Ecommerce

Learn how Precision Medical leveraged OneWorld to cut the cost of billing in half and added $2.5M in annual revenue.

The price of bitcoin is expected to more than double next year in part because of slower growth in the supply of the digital currency, Reuters reports.

Bitcoin hit $500 last month for the first time since August last year, with Chinese demand for a pyramid scheme set up by a Russian fraudster cited as a reason for the increase. Experts see the price testing its 2013 highs of above $1,100 next year. Read more.


IRS Faulted Over Taxpayer Authentication

An in-house watchdog says authentication weaknesses have left tax account information vulnerable to “unscrupulous individuals.”

Katie Kuehner-Hebert

Low Supply Seen Pushing Bitcoin Price Up

The halving of the reward for bitcoin mining next year will dampen supply, contributing to a possible doubling in the price of the cryptocurrency.

Matthew Heller

CFOs on the Move: Week Ending Dec. 25

Sotheby’s, Kelly Services, Tuesday Morning, Cardtronics, Newgistics, Ramco-Gershenson Properties Trust, Lantheus Holdings

Joan Urdang

Valeant to Take $150M Hit From Walgreens Deal

Valeant’s revenue hit will include the value of the drugs shifted to consignment status and expected delays recognizing revenue from the Walgreens deal.

Matthew Heller


More financial insights in the CFO library.